R. Keith Frank, Ph.D.


Dr. Frank is a co-founder of IsoTherapeutics. A synthetic organic chemist by training, he has spent the first 23 years of his career at The Dow Chemical Company. His principle activity was in the development of radiopharmaceuticals, including two approved products (Quadramet® and I-125 IotrexTM). He holds 22 US patents and has over 30 publications.

Dr. Frank initiated and led ChelaMedSM radiopharmaceutical services at Dow. In that role he helped other companies develop radiopharmaceuticals and taught them about isotopes and conjugation chemistry. He also has expertise in developing tumors in animal studies and in radiation dosimetry.

Jaime (Jim) Simón, Ph.D.


Dr. Simón is a co-founder of IsoTherapeutics. He is a radiochemist by training and spent 25 years at The Dow Chemical Company where he was responsible for a group dedicated to developing new pharmaceutical technologies. He holds over 50 US patents, including the key patents covering Quadramet® (153Sm-EDTMP) for the treatment of bone cancer and STR (166Ho-DOTMP) for safely ablating bone marrow prior to bone marrow transplants. Dr Simón has over 70 publications.

Lance Cooper

Director Of Business Development And Chemist

Lance Cooper has more than thirty years of increasing and varied responsibilities in the chemical industry that has included:

  • Customer Technical Service
  • Manufacturing Issue Management
  • Product Stewardship Management
  • Chelation / Metal Ion Control Expertise
  • Detergent / Cleaning Formulation Development
  • Polyurethane Technology Expertise
  • Product specification development
  • Quality Management System Expertise


Stephen Davis

Quality Control Manager and Human Resources Director

George M. St. George, Ph.D.

Senior Scientist and Quality Assurance Manager

Scot Ellebracht


Rhonda Key


Natalie Jennings

Quality Associate

Tim Jones


Kim Miller

Executive Assistant and Purchasing Manager

Board of Directors

Keith Frank

Jim Simón

Lonnie Key

Steve Ellebracht

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Melbourne (Australia) – 27 February 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.
In line with Telix’s continued investment in the vertical integration of supply chain, manufacturing and development capabilities, the acquisition is expected to further enhance Telix’s in-house drug development capabilities. A key driver for the acquisition is to enable Telix to bring select aspects of its development programs in-house, with the goal of reducing cost and time to achieve technical milestones.
The acquisition will also expand Telix’s U.S. manufacturing footprint with a site that includes a GMP1 clean room and production infrastructure suitable for clinical use. The site also has extensive capacity to process a wide variety of therapeutic isotopes used in Telix’s development portfolio.